Introduction
Hepatitis B e antigen (HBeAg), originally described by Magnius & Espmark (1972) , is a secretory protein that occurs in soluble form in sera from individuals infected with hepatitis B virus (HBV) and signals a contagious state of the disease (Alter et al., 1976; Okada et at., 1976; Bonino et al., 1991) . The function of HBeAg has been suggested to be the protection of HBV-infected hepatocytes from the host immune surveillance (Uy et al., 1986; Milich et al., 1990; Bonino et al., 1991) .
HBeAg shares 149 amino acids (aa) with the HBV nucleocapsid protein, immunologically defined as the core antigen (HbcAg). HBeAg determinants can be revealed on native HBcAg by treatment with detergent or by limited proteolysis (Budkowska et al., 1979) . The first AUG in the C-terminal open reading frame corresponds to the start of transcription of the mRNA for the HBeAg precursor while the second in-frame AUG corresponds to that of HBcAg. Intracellular HBeAg including the precore residues -29 to -1 contains a signal sequence that guides the protein to the endoplasmic reticulum, where the precursor HBeAg residues -29 to -11 are cleaved off (Standing et al., 1988) . After another proteolytic cleavage, between aa 149 and 150, the remaining part is secreted into the circulation (Ou et al., 1986) . Thus, serum HBeAg is considered to consist of aa -10 to -1 of the precore region (Bruss & Gerlich, 1988) plus residues 1 to 149 of HBcAg (Takahashi et al., 1983) . However, HBeAg containing the whole precore region has also been found in human sera (Takahashi et al., 1992) .
Two major antigenic regions of HBeAg have been identified (Imai et al., 1982; Ferns & Tedder, 1984; Salfeld et al., 1989) . Salfeld et al. (1989) described an antigenic region within the HBc/eAg sequence which resided around aa 130 to 138 but was suggested to require the presence of a part of the N-terminal region of the HBcAg sequence in order to be recognized as a fusion protein (HBe2; Salfeld et al., 1989) . However, it has been shown that monoclonal antibodies (MAbs) and human sera may recognize the region around aa 130 as a linear 0001-1494 © 1993 SGM epitope which has been mimicked by synthetic peptides (S/illberg et al., 1991a, c; Bichko et al., 1992) . In this paper, we report on the immunochemical characterization of the C-terminal part of the HBeAg at the resolution of a single amino acid.
Methods
Human HBeAg, anti-HBe and anti-HBc positive sera. A total of 22 human sera from chronic carriers of HBsAg were selected from consecutive sera sent to the Department of Virology at the National Bacteriological Laboratory, Stockholm from 1988 to 1992. All sera were serologically defined as regards HBV status using commercial radioimmunoassays (RIAs; Abbott). Six of the sera were found to be positive for HBsAg, HBeAg and anti-HBc in these RIAs, and 16 were found to be positive for HBsAg, anti-HBe and anti-HBc. All of the 16 sera that were positive for anti-HBe in RIA were also found to be reactive to a peptide covering residues 121 to 140 of HBeAg (S~illberg et aL, 1991a) .
MAbs. The production and characterization of the MAb to HBec~ (141/03) and HBefl-specific MAbs (57/8, 141/158 and 141/207) have been described elsewhere (Noah & Harthus, 1987; S/illberg et al., 1991 a, b) . The MAbs were obtained by screening primary hybridomas for activity in the Enzygnost anti-HBe assay (Behringwerke). The MAbs HBeOT6P and HBeOT7Q were raised against recombinant HBcAg (rHBcAg, subtype adw; Ono et at., 1983) . The primary hybridoma clones were screened for MAb production by enzyme immunoassays (EIAs) using recombinant HBeAg (rHBeAg; Biogen) or rttBcAg (Chiron Corporation, P. Sillekens et al., unpublished) . They will be referred to as MAbs against rHBeAg in the following text.
The MAbs 14Ell, 14G3, 14E12, 13D9, 13B1, 14D5, 10F10, 13C9, 10C6 and 13D3 were raised against SDS-denaturated rHBcAg (drHBcAg of ayw subtype; Bichko et al., 1985 Bichko et al., , 1992 , which also was used for the screening of primary hybridomas. These will be referred to as MAbs against drHBcAg in the following text.
Characterization of MAbs in commercial assays. The MAbs were tested for anti-HBc and anti-HBe specificity using Corab and HBe RIA (Abbott). All HBe MAbs were also analysed for HBe specificity using the semi-automated Abbott HBe IMX system.
In the anti-HBc and anti-HBe RIAs, and in the anti-HBe IMX assay, all MAbs were diluted 1 : 100 in the negative control serum provided with the assay, and the mixture was then tested for its ability to inhibit binding to 125I-labelled human anti-HBc and anti-HBe according to the manufacturer's instructions. Reactions giving > 50% inhibition of radiolabelled antibody are regarded as positive. In the anti-HBe IMX assay, a sample to cut-off ratio (S/CO) less than 1.0 is regarded as reactive.
HBcAg-fr coat protein (CP) fusion proteins. The amino acid numbering is given according to translation starting at the second AUG. A set of fusion proteins containing HBcAg successively truncated from the N to C terminus was constructed by unidirectional shortening of the C gene fragment (encoding aa 29 to 176) cloned into the polylinker at a position between aa 1 and 2 of the RNA phage fr CP gene (frCP). The latter has been expressed in Escherichia coli under control of the tryptophan operon promoter (Kozlovskaya et al., 1986) . Restriction endonuclease cleavage sites at the 5' part of the polylinker were used for unidirectional truncation of the HBeAg gene fragment by using nucleases Exo III and S1, according to the method of Henikoff (1984) . Proteins containing in-frame deletions were expressed in E. coli from recombinant plasmids and selected by Western blotting with rabbit antibodies against frCP. The sequences of the recombinant genes were analysed by the dideoxynucleotide chain termination method (Sanger et al., 1977) .
Proteins were separated by SDS-PAGE (Laemmli, 1970) . Western blotting was performed essentially as described by Towbin et al. (1979) . Blotted nitrocellulose membranes were incubated overnight at 4 °C with various dilutions of the MAbs. Bound MAbs were detected by incubation with horseradish peroxidase (HRPO)-conjugated rabbit anti-mouse Ig (Sigma) for 2 h at 37 °C followed by the addition of odianisidine substrate. Galibert et al., 1979) and analogues thereof, in which each amino acid within residues 124 to 135 and 131 to 146 was sequentially substituted by alanine or glycine, were synthesized according to a previously described method (S/illberg et al., 1991 c) . The peptides were dissolved in water at a concentration of 1 mg/ml. When analysed by HPLC, peptides were found to be at least 70 % pure and were used without further purification.
Solid
Peptide-based EIAs. Peptides were coated onto microtitre plates at a concentration of 1 ~tg/ml in 0-5 M-sodium carbonate buffer pH 9.6 and kept overnight at 4 °C. The plates were incubated for 1 h at 37 °C with MAbs, diluted 1:1000 and 1:10000 in PBS with 0.05% Tween 20 (PBST), 0'5 % BSA and 10% fetal calf serum. Bound MAbs were then detected by HRPO-conjugated rabbit anti-mouse Ig (Dakopatts) diluted 1 : 3000 in PBST with 0.5 % BSA. After a 1 h incubation at 37 °C with the conjugate, bound conjugate was measured by incubation with o-phenylenediamine (Dako). Absorbances were read at 492 nm. All human sera were tested with peptide-coated plates, at a dilution of 1 : 100 in PBST with 1% BSA and 2% goat serum. Bound serum IgG1 was located by a MAb to human IgG1 (clone NL16; Unipath) for 1 h at 37 °C. Bound MAb was then assayed as described above.
Assays for MAbs" ability to bind to recombinant and native HBeAg.
The binding of MAbs to denaturated recombinant HBcAg was performed according to a method previously described (S~illberg et al., 1989) in which SDS-treated HBcAg was coated onto microplates and assayed as described above.
The binding of MAbs to native HBeAg was performed using soft microtitre plates (Dynatech) coated with the different MAbs. To each MAb, 50 gl portions of recombinant HBeAg (neutralizing reagent, HBe RIA, Abbott) and of each of the six human sera containing native HBeAg (diluted 1:100) were added. These were incubated with the MAbs for 90 min at 37 °C. The plate was washed and incubated with radiolabelled human anti-HBe (HBe RIA) to reveal bound HBeAg. The plates were then cut and the radioactivity in each well was measured in a ?,-counter. Sample to negative ratios were obtained by dividing the c.p.m, of each individual HBeAg sample with the c.p.m. of each well to which HBeAg-negative sera (HBe RIA) had been added. The cutoff was set at the same level as that for the commercial HBeAg RIA, 3.1 times the c.p.m, of the HBeAg-negative sera. (Fig. la) . The MAb HBeOT7Q against rHBeAg and MAb 14Ell against drHBcAg recognized proteins covering residues 101 to 176, 121 to 176 and 134 to 176 (Fig. lb, c) . The MAb 10C6 against drHBcAg recognized proteins containing fragments 121 to 176, 134 to 176 and 138 to 176 (Fig.  1 d) , and the MAb 13D3 against drHBcAg recognized fragments 139 to 176 and 140 to 176 (Fig. 1 e) . Additional bands at low M r are likely to be intracellularly degraded HBc-containing products. The peptide 130-PAYRPPNAPILSTLPETT-147, representing the C-terminal part of HBeAg (without the two C-terminal valine residues), as well as its substitution analogues were tested in EIA with the MAbs against rHBeAg and drHBcAg recognizing this region, according to epitope mapping with the fusion proteins described above. The MAbs recognized overlapping epitopes 133-RPPNAP-138, 135-PNAPIL-140, 138-PIL-STLPE-145 and 143-LPET-146 (Fig. 2) .
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The IgG1 reactions for six of the 16 human sera, with the substitution peptide analogues of region 121 to 136, are given in Fig. 3 . A summary of the IgG1 recognition sites of the 16 human anti-HBe positive sera is given in Fig. 4 , in relation to the epitope locations of 14 MAbs to the Cterminal domain of HBeAg. All sera recognized various sites within the region 124 to 133, whereas only MAbs to HBefl (57/8, 141/158 and 141/207) show recognition sites corresponding to the ones of the human sera. A summary of the ability of each serum IgG1 and MAb to bind native HBeAg and denatured HBcAg is also given in Fig. 4 . As shown, human antibodies and MAbs with similar recognition sites bind serum HBeAg, whereas the MAbs against rHBeAg and drHBcAg do not. However, all sera and all MAbs show strong reactivity to drHBcAg (data not shown).
Discussion
Two major HBe determinants have been observed by several authors (Imai et al., 1982; Ferns & Tedder, 1984; Salfeld et al., 1989) . Mutual correspondence of these determinants termed HBe-a and HBe-b (Imai et al., 1982) , e-e and e-fl (Ferns & Tedder, 1984) or HBel and HBe2 (Salfeld et al., 1989) has not been investigated thoroughly. It may be assumed that HBe-a, HBe~ and HBel constitute one group of similar or identical determinants residing around aa 80 of the HBeAg whereas HBe-b, HBefl and HBe2 form the other group at its carboxy-terminal part (Salfeld et al., 1989; Sfillberg et al., 1991a, b; Bichko et al., 1992) . Here we report the immunochemical identification of several overlapping but functionally distinct epitopes at the carboxy-terminal part (residues 124 to 146) of the HBeAg using recombinant proteins and synthetic peptides. Based on the findings reported herein, we consider the MAbs against rHBeAg (HBeOT6P and HBeOT7Q) and drHBcAg (14Et 1, 14G3, 14E12, 13D9, 13B1, 14D5, 10F10, 13C9, 10C6 and 13D3) to be similar to the MAbs reported by Salfeld et al. (1989) which had recognition sites around residue 140 and for which the epitope was termed HBe2. We define HBefl and the HBe2 regions as two domains structurally separated by the proline at position 134 in the HBeAg sequence, by using a panel of murine MAbs and human sera. The recognition sites were mapped to a single amino acid resolution. Mapping data obtained by the use of recombinant proteins and synthetic peptides were found to corroborate each other. Our findings resolve earlier observed discrepancies with respect to the immune recognition of the C-terminal part of the HBeAg (Salfeld et al., 1989 ; S~tllberg et al., 1991 b; Bichko et al., 1992) . The C-terminal part of the HBeAg, residues 121 to 149, induces MAbs that recognize overlapping epitopes, which is the most likely reason for the variation in the previous observations. Also, in the different reports, varying selection criteria for the primary hybridomas have been used, such as specific inhibition of human anti-HBe (Imai et al., 1982; Ferns & Tedder, 1984; Noah & Harthus, 1987) , or direct binding to rHBeAg or drHBcAg (P. Sillekens et al., unpublished; Bichko et al., 1992) .
Taken together, our data would suggest that the main surface-exposed part of the C terminus of the native HBeAg is the region 124 to 133, whereas the region 134 to 146 in most cases seems to be inaccessible to antibodies. Evidence for this is that (i) all HBefl-specific MAbs recognizing residues 128 to 133 can capture recombinant and native HBeAg, whereas the other MAbs can not, and (ii) the HBefl-specific MAbs recognizing residues 128 to 133 compete with human antibodies in commercial assays, whereas the MAbs raised against rHBeAg and drHBcAg, recognizing sites only two residues closer to the C terminus, do not. In structural terms, this is possibly due to a predicted turn induced by the two prolines at residues 134 and 135 (Chou & Fasman, 1978) , which would make the Cterminal part 136 to 149 internal and thereby less accessible to antibodies.
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